{
  "DOI": "10.1038/s41431-019-0540-0",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-019-0540-0",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eDespite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of three anti-cancer drugs (fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the risk of severe, potentially fatal, toxicity (such as diarrhoea, hand-foot syndrome, mucositis or myelosuppression). Dihydropyrimidine dehydrogenase (DPD, encoded by the\u003cjats:italic\u003eDPYD\u003c/jats:italic\u003egene) enzyme deficiency increases risk of fluoropyrimidine-induced toxicity. The\u003cjats:italic\u003eDPYD-\u003c/jats:italic\u003egene activity score, determined by four\u003cjats:italic\u003eDPYD\u003c/jats:italic\u003evariants, predicts DPD activity and can be used to optimize an individual’s starting dose. The gene activity score ranges from 0 (no DPD activity) to 2 (normal DPD activity). In case it is not possible to calculate the gene activity score based on\u003cjats:italic\u003eDPYD\u003c/jats:italic\u003egenotype, we recommend to determine the DPD activity and adjust the initial dose based on available data. For patients initiating 5-fluorouracil or capecitabine: subjects with a gene activity score of 0 are recommended to avoid systemic and cutaneous 5-fluorouracil or capecitabine; subjects with a gene activity score of 1 or 1.5 are recommended to initiate therapy with 50% the standard dose of 5-fluorouracil or capecitabine. For subjects initiating tegafur: subjects with a gene activity score of 0, 1 or 1.5 are recommended to avoid tegafur. Subjects with a gene activity score of 2 (reference) should receive a standard dose. Based on the DPWG clinical implication score,\u003cjats:italic\u003eDPYD\u003c/jats:italic\u003egenotyping is considered “essential”, therefore directing\u003cjats:italic\u003eDPYD\u003c/jats:italic\u003etesting prior to initiating fluoropyrimidines.\u003c/jats:p\u003e",
  "alternative-id": [
    "540"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "2 August 2018"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "7 October 2019"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "13 October 2019"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "19 November 2019"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that they have no conflict of interest."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Lunenburg",
      "given": "Carin A. T. C.",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-7728-8802",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "van der Wouden",
      "given": "Cathelijne H.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Nijenhuis",
      "given": "Marga",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Crommentuijn-van Rhenen",
      "given": "Mandy H.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "de Boer-Veger",
      "given": "Nienke J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Buunk",
      "given": "Anne Marie",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Houwink",
      "given": "Elisa J. F.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mulder",
      "given": "Hans",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rongen",
      "given": "Gerard A.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "van Schaik",
      "given": "Ron H. N.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "van der Weide",
      "given": "Jan",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wilffert",
      "given": "Bob",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Deneer",
      "given": "Vera H. M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Swen",
      "given": "Jesse J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Guchelaar",
      "given": "Henk-Jan",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2019,
        11,
        19
      ]
    ],
    "date-time": "2019-11-19T18:03:02Z",
    "timestamp": 1574186582000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        20
      ]
    ],
    "date-time": "2023-05-20T21:00:47Z",
    "timestamp": 1684616447000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        29
      ]
    ],
    "date-time": "2024-04-29T18:24:58Z",
    "timestamp": 1714415098052
  },
  "is-referenced-by-count": 119,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "4",
  "issued": {
    "date-parts": [
      [
        2019,
        11,
        19
      ]
    ]
  },
  "journal-issue": {
    "issue": "4",
    "published-print": {
      "date-parts": [
        [
          2020,
          4
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2019,
            11,
            19
          ]
        ],
        "date-time": "2019-11-19T00:00:00Z",
        "timestamp": 1574121600000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2019,
            11,
            19
          ]
        ],
        "date-time": "2019-11-19T00:00:00Z",
        "timestamp": 1574121600000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/s41431-019-0540-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-019-0540-0",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-019-0540-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "508-517",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2019,
        11,
        19
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2019,
        11,
        19
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        4
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1371/journal.pmed.0040209",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "e209",
      "journal-title": "PLoS Med",
      "key": "540_CR1",
      "unstructured": "Swen JJ, Huizinga TW, Gelderblom H, De Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209.",
      "volume": "4",
      "year": "2007"
    },
    {
      "DOI": "10.1038/sj.clpt.6100507",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "781",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR2",
      "unstructured": "Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharm Ther. 2008;83:781–7.",
      "volume": "83",
      "year": "2008"
    },
    {
      "key": "540_CR3",
      "unstructured": "European Association for Clinical Pharmacology and Therapeutics (EACPT). Available from: https://www.eacpt.eu/. [Accessed November 2017]."
    },
    {
      "key": "540_CR4",
      "unstructured": "European Association of Hospital Pharmacists (EAHP). Available from: https://www.eahp.eu/. [Accessed November 2017]."
    },
    {
      "DOI": "10.1002/cpt.911",
      "author": "U Amstutz",
      "doi-asserted-by": "publisher",
      "first-page": "210",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR5",
      "unstructured": "Amstutz U, Henricks LM, Offer SM, Barbino J, Schellens JHM, Swen JJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharm Ther. 2018;103:210–6.",
      "volume": "103",
      "year": "2018"
    },
    {
      "DOI": "10.1002/cpt.762",
      "doi-asserted-by": "crossref",
      "key": "540_CR6",
      "unstructured": "Bank PC, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the Dutch pharmacogenetics working group. Clin Pharmacol Ther. 2018;103:599–618."
    },
    {
      "DOI": "10.1038/clpt.2011.34",
      "author": "JJ Swen",
      "doi-asserted-by": "publisher",
      "first-page": "662",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR7",
      "unstructured": "Swen JJ, Nijenhuis M, De Boer BA, Grandia L, Maitland-van der Zee AH, Mulder H. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharm Ther. 2011;89:662–73.",
      "volume": "89",
      "year": "2011"
    },
    {
      "DOI": "10.1136/gutjnl-2013-306571",
      "author": "D Rosmarin",
      "doi-asserted-by": "publisher",
      "first-page": "111",
      "journal-title": "Gut",
      "key": "540_CR8",
      "unstructured": "Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64:111–20.",
      "volume": "64",
      "year": "2015"
    },
    {
      "DOI": "10.1056/NEJM200009283431302",
      "author": "LB Saltz",
      "doi-asserted-by": "publisher",
      "first-page": "905",
      "journal-title": "N Engl J Med",
      "key": "540_CR9",
      "unstructured": "Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.",
      "volume": "343",
      "year": "2000"
    },
    {
      "author": "TK Froehlich",
      "first-page": "730",
      "journal-title": "Int J Cancer",
      "key": "540_CR10",
      "unstructured": "Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136:730–9.",
      "volume": "136",
      "year": "2015"
    },
    {
      "DOI": "10.1097/FPC.0b013e32833c6107",
      "author": "CF Thorn",
      "doi-asserted-by": "crossref",
      "first-page": "237",
      "journal-title": "Pharmacogenet Genomics",
      "key": "540_CR11",
      "unstructured": "Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237–42.",
      "volume": "21",
      "year": "2011"
    },
    {
      "key": "540_CR12",
      "unstructured": "NCBI: National Center for Biotechnology Information. DPYD dihydropyrimidine dehydrogenase [Homo sapiens (human)]. Gene. 2017. Available from: https://www.ncbi.nlm.nih.gov/gene/1806. [Accessed October 2017]."
    },
    {
      "DOI": "10.1002/ijc.29654",
      "author": "G Toffoli",
      "doi-asserted-by": "publisher",
      "first-page": "2971",
      "journal-title": "Int J Cancer",
      "key": "540_CR13",
      "unstructured": "Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137:2971–80.",
      "volume": "137",
      "year": "2015"
    },
    {
      "key": "540_CR14",
      "unstructured": "Genome Aggregation Database (gnomAD). GnomAD browser (Beta) 2017. Available from: http://gnomad.broadinstitute.org/. [Accessed July 2017]."
    },
    {
      "key": "540_CR15",
      "unstructured": "Ensembl: Gene: DPYD ENSG00000188641. 2017. Available from: http://www.ensembl.org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=ENSG00000188641;r=1:97077743-97921049. [Accessed July 2017]."
    },
    {
      "DOI": "10.1002/cpt.531",
      "author": "T Elraiyah",
      "doi-asserted-by": "publisher",
      "first-page": "382",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR16",
      "unstructured": "Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, et al. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharm Ther. 2017;101:382–90.",
      "volume": "101",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ejca.2003.12.004",
      "author": "AB van Kuilenburg",
      "doi-asserted-by": "publisher",
      "first-page": "939",
      "journal-title": "Eur J Cancer",
      "key": "540_CR17",
      "unstructured": "van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40:939–50.",
      "volume": "40",
      "year": "2004"
    },
    {
      "DOI": "10.1200/JCO.2015.63.1325",
      "author": "MJ Deenen",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "journal-title": "J Clin Oncol",
      "key": "540_CR18",
      "unstructured": "Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34:227–34.",
      "volume": "34",
      "year": "2016"
    },
    {
      "DOI": "10.1002/cpt.1020",
      "doi-asserted-by": "crossref",
      "key": "540_CR19",
      "unstructured": "Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, et al. Gene-specific variant classifier (DPYD-Varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clin Pharmacol Ther. 2018;104:709–18."
    },
    {
      "DOI": "10.2217/pgs.15.70",
      "doi-asserted-by": "crossref",
      "key": "540_CR20",
      "unstructured": "Henricks LM, Lunenburg CATC, Meulendijks D, Gelderblom H, Cats A, Swen JJ, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277–86."
    },
    {
      "DOI": "10.2165/00003088-200645060-00002",
      "author": "SA Ploylearmsaeng",
      "doi-asserted-by": "publisher",
      "first-page": "567",
      "journal-title": "Clin Pharmacokinet",
      "key": "540_CR21",
      "unstructured": "Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45:567–92.",
      "volume": "45",
      "year": "2006"
    },
    {
      "DOI": "10.1093/clinchem/46.1.9",
      "author": "ABP Van Kuilenburg",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "journal-title": "Clin Chem",
      "key": "540_CR22",
      "unstructured": "Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46:9–17.",
      "volume": "46",
      "year": "2000"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-03-0374",
      "author": "LK Mattison",
      "doi-asserted-by": "publisher",
      "first-page": "2652",
      "journal-title": "Clin Cancer Res",
      "key": "540_CR23",
      "unstructured": "Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 2004;10:2652–8.",
      "volume": "10",
      "year": "2004"
    },
    {
      "DOI": "10.1097/01.ftd.0000245771.82720.c7",
      "author": "J Ciccolini",
      "doi-asserted-by": "publisher",
      "first-page": "678",
      "journal-title": "Ther Drug Monit",
      "key": "540_CR24",
      "unstructured": "Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28:678–85.",
      "volume": "28",
      "year": "2006"
    },
    {
      "DOI": "10.1159/000099984",
      "author": "ZW Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "127",
      "journal-title": "Chemotherapy",
      "key": "540_CR25",
      "unstructured": "Zhou ZW, Wang GQ, Wan de S, Lu ZH, Chen YB, Li S, et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy. 2007;53:127–31.",
      "volume": "53",
      "year": "2007"
    },
    {
      "DOI": "10.1038/bjc.2017.94",
      "author": "D Meulendijks",
      "doi-asserted-by": "publisher",
      "first-page": "1415",
      "journal-title": "Br J Cancer",
      "key": "540_CR26",
      "unstructured": "Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, De Vries N, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116:1415–24.",
      "volume": "116",
      "year": "2017"
    },
    {
      "DOI": "10.1038/tpj.2013.25",
      "author": "MC van Staveren",
      "doi-asserted-by": "publisher",
      "first-page": "389",
      "journal-title": "Pharmacogenomics J",
      "key": "540_CR27",
      "unstructured": "van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013;13:389–95.",
      "volume": "13",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.ctrv.2016.08.002",
      "author": "D Meulendijks",
      "doi-asserted-by": "publisher",
      "first-page": "23",
      "journal-title": "Cancer Treat Rev",
      "key": "540_CR28",
      "unstructured": "Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity—ready for clinical practice? Cancer Treat Rev. 2016;50:23–34.",
      "volume": "50",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nrd3921",
      "author": "M Pirmohamed",
      "doi-asserted-by": "publisher",
      "first-page": "3",
      "journal-title": "Nat Rev Drug Discov",
      "key": "540_CR29",
      "unstructured": "Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Discov. 2013;12:3–4.",
      "volume": "12",
      "year": "2013"
    },
    {
      "DOI": "10.1038/clpt.2010.310",
      "author": "RB Altman",
      "doi-asserted-by": "publisher",
      "first-page": "348",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR30",
      "unstructured": "Altman RB. Pharmacogenomics: “noninferiority” is sufficient for initial implementation. Clin Pharm Ther. 2011;89:348–50.",
      "volume": "89",
      "year": "2011"
    },
    {
      "DOI": "10.1016/j.ejca.2015.11.008",
      "author": "CATC Lunenburg",
      "doi-asserted-by": "publisher",
      "first-page": "40",
      "journal-title": "Eur J Cancer",
      "key": "540_CR31",
      "unstructured": "Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40–8.",
      "volume": "54",
      "year": "2016"
    },
    {
      "DOI": "10.1002/cpt.1049",
      "doi-asserted-by": "crossref",
      "key": "540_CR32",
      "unstructured": "Swen JJ, Nijenhuis M, van Rhenen M, De Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Pharmacogenetic information in clinical guidelines: the European Perspective. Clin Pharmacol Ther. 2018;103:795–801."
    },
    {
      "DOI": "10.1038/clpt.2013.172",
      "author": "KE Caudle",
      "doi-asserted-by": "publisher",
      "first-page": "640",
      "journal-title": "Clin Pharm Ther",
      "key": "540_CR33",
      "unstructured": "Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharm Ther. 2013;94:640–5.",
      "volume": "94",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.bulcan.2018.02.001",
      "author": "MA Loriot",
      "doi-asserted-by": "publisher",
      "first-page": "397",
      "journal-title": "Bull Cancer",
      "key": "540_CR34",
      "unstructured": "Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G. et al. Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer. 2018;105:397–407.",
      "volume": "105",
      "year": "2018"
    },
    {
      "key": "540_CR35",
      "unstructured": "CPIC: Clinical Pharmacogenetics Implementation Consortium. Annotation of CPIC guideline for capecitabine and DPYD. PharmGKB; 2018 Available from: https://www.pharmgkb.org/guidelineAnnotation/PA166109594. [Accessed November 2018]."
    },
    {
      "key": "540_CR36",
      "unstructured": "KNMP: Royal Dutch Society for the Advancement of Pharmacy. Fluorouracil/Capecitabine DPD gene activity score and guidelines. KNMP, Royal Dutch Society for the Advancement of Pharmacy; 2015. Available from: https://kennisbank.knmp.nl/article/farmacogenetica/2552-4893-4894.html. [Accessed May 2017]."
    }
  ],
  "reference-count": 36,
  "references-count": 36,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-019-0540-0"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "28"
}